Ascentage Pharma to Present P-II Study Results of Lisaftoclax (APG-2575) for Chronic Lymphocytic Leukemia at ASH 2022
- The P-II study evaluates lisaftoclax (400/600/800mg) as monothx. or in combination with acalabrutinib or rituximab in patients with r/r CLL/SLL for six 28-day cycles. 12% had progressed on BTKi & after venetoclax therapy
- The results showed an ORR of 98% with lisaftoclax + acalabrutinib and 87% with lisaftoclax + rituximab & the results from the monothx. cohort are comparable to prior studies along with favorable safety & promising efficacy with high response rates
- The combination therapies maintained a low incidence of TLS & hematologic AEs, grade ≥3 neutropenia was manageable with growth factor support in 13%, no discontinuations due to lisaftoclax alone or combined with other agents with no dose-limiting toxicities & no drug-drug interactions
Ref: Businesswire | Image: Ascentage
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.